Should I buy or sell Tempest Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares. View TPST analyst ratings or view top-rated stocks .

What is Tempest Therapeutics' stock price target for 2024?

4 brokerages have issued 12 month target prices for Tempest Therapeutics' stock. Their TPST share price targets range from $13.00 to $47.00. On average, they expect the company's share price to reach $22.25 in the next twelve months. This suggests a possible upside of 580.4% from the stock's current price. View analysts price targets for TPST or view top-rated stocks among Wall Street analysts .

How have TPST shares performed in 2024?

Tempest Therapeutics' stock was trading at $4.40 at the start of the year. Since then, TPST stock has decreased by 25.7% and is now trading at $3.27. View the best growth stocks for 2024 here .

Are investors shorting Tempest Therapeutics?

Tempest Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 969,700 shares, an increase of 26.5% from the March 15th total of 766,800 shares. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 6.1% of the company's stock are short sold. View Tempest Therapeutics' Short Interest .

When is Tempest Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TPST earnings forecast .

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) issued its earnings results on Tuesday, March, 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04.

When did Tempest Therapeutics' stock split?

Tempest Therapeutics's stock reverse split before market open on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Tempest Therapeutics?

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TPST

Tempest Therapeutics (TPST) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free TPST Stock Alerts

$3.31

+0.04 (+1.22%)

(As of 11:39 AM ET)

Compare

Today's Range: $3.26
▼
$3.34
50-Day Range: $3.16
▼
$5.44
52-Week Range: $0.17
▼
$9.77

Volume: 90,760 shs
Average Volume: 978,082 shs
Market Capitalization: $73.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.25

Get Tempest Therapeutics alerts:

Tempest Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 580.4% Upside
$22.25 Price Target
Short Interest: Bearish
6.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.73
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.58) to ($1.64) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

769th out of 914 stocks

Pharmaceutical Preparations Industry

353rd out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Tempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Tempest Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.09% of the float of Tempest Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tempest Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tempest Therapeutics has recently increased by 26.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tempest Therapeutics does not currently pay a dividend.
Dividend Growth
Tempest Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TPST.

3.7

News and Social Media Coverage

News Sentiment
Tempest Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Tempest Therapeutics this week, compared to 2 articles on an average week.
Search Interest
21 people have searched for TPST on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
MarketBeat Follows
22 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 340% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.80% of the stock of Tempest Therapeutics is held by insiders.
Percentage Held by Institutions
Only 22.52% of the stock of Tempest Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tempest Therapeutics are expected to decrease in the coming year, from ($1.58) to ($1.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tempest Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tempest Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tempest Therapeutics has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

About Tempest Therapeutics Stock (NASDAQ:TPST)

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

TPST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TPST Stock News Headlines

April 15, 2024 | americanbankingnews.com

Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 26.5% in March

April 14, 2024 | americanbankingnews.com

Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 6.8%

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

April 9, 2024 | markets.businessinsider.com

Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments

April 9, 2024 | finance.yahoo.com

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

April 9, 2024 | globenewswire.com

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

April 6, 2024 | uk.investing.com

Tempest Therapeutics moves TPST-1120 into phase 3 trial

April 4, 2024 | finance.yahoo.com

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

April 4, 2024 | globenewswire.com

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

March 21, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)

March 20, 2024 | finanznachrichten.de

Tempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Update

March 19, 2024 | investorplace.com

TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023

March 19, 2024 | finance.yahoo.com

Tempest Reports Year End 2023 Financial Results and Provides Business Update

March 19, 2024 | globenewswire.com

Tempest Reports Year End 2023 Financial Results and Provides Business Update

March 14, 2024 | businesswire.com

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospects

March 12, 2024 | finance.yahoo.com

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

March 5, 2024 | globenewswire.com

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

February 26, 2024 | finance.yahoo.com

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

January 30, 2024 | finance.yahoo.com

Tempest Therapeutics, Inc. (TPST)

December 28, 2023 | benzinga.com

Tempest Therapeutics Stock (NASDAQ:TPST), Short Interest Report

December 11, 2023 | benzinga.com

Tempest Therapeutics Stock (NASDAQ:TPST) Insider Trades

December 2, 2023 | finanznachrichten.de

Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 1, 2023 | finance.yahoo.com

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 20, 2023 | finance.yahoo.com

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

November 11, 2023 | markets.businessinsider.com

Growth Potential and Strategic Partnerships: Reasons for Aydin Huseynov’s Buy Rating on Tempest Therapeutics

See More Headlines

Receive TPST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:TPST
CUSIP: N/A
CIK: 1544227
Web: www.millendo.com
Phone: 415-798-8589
Fax: N/A
Employees: 17
Year Founded: 2012

Price Target and Rating

Average Stock Price Target: $22.25
High Stock Price Target: $47.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +580.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -283.87%
Return on Assets: -82.11%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 4.29
Quick Ratio: 4.29

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.39 per share
Price / Book: 2.35

Miscellaneous

Outstanding Shares: 22,190,000
Free Float: 20,905,000
Market Cap: $72.56 million
Optionable: Optionable
Beta: -1.76

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Stephen R. Brady J.D. (Age 54)
LLM, CEO, President & Director
Comp: $740.95k
Dr. Samuel Whiting M.D. (Age 58)
Ph.D., Executive VP & Chief Medical Officer
Comp: $591.23k
Mr. Nicholas Maestas (Age 44)
VP of Strategy & Finance and Secretary
Mr. Justin Trojanowski (Age 36)
Corporate Controller, Treasurer & Principal Accounting Officer
Ms. Lindsay Young
Head of Human Resources
Dr. Sharon Sakai Ph.D.
RAC, Head of Regulatory & Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

TPST Stock Analysis - Frequently Asked Questions

Should I buy or sell Tempest Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares.
View TPST analyst ratings or view top-rated stocks.
What is Tempest Therapeutics' stock price target for 2024?: 4 brokerages have issued 12 month target prices for Tempest Therapeutics' stock. Their TPST share price targets range from $13.00 to $47.00. On average, they expect the company's share price to reach $22.25 in the next twelve months. This suggests a possible upside of 580.4% from the stock's current price.
View analysts price targets for TPST or view top-rated stocks among Wall Street analysts.
How have TPST shares performed in 2024?: Tempest Therapeutics' stock was trading at $4.40 at the start of the year. Since then, TPST stock has decreased by 25.7% and is now trading at $3.27.
View the best growth stocks for 2024 here.
Are investors shorting Tempest Therapeutics?: Tempest Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 969,700 shares, an increase of 26.5% from the March 15th total of 766,800 shares. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 6.1% of the company's stock are short sold.
View Tempest Therapeutics' Short Interest.

When is Tempest Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TPST earnings forecast.
How were Tempest Therapeutics' earnings last quarter?: Tempest Therapeutics, Inc. (NASDAQ:TPST) issued its earnings results on Tuesday, March, 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04.
When did Tempest Therapeutics' stock split?: Tempest Therapeutics's stock reverse split before market open on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of Tempest Therapeutics?: Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TPST) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tempest Therapeutics (TPST) Stock Price, News & Analysis

Tempest Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Tempest Therapeutics Stock (NASDAQ:TPST)

TPST Stock Price History

TPST Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

TPST Stock Analysis - Frequently Asked Questions

Overall MarketRank^™